Study Title: A phase I/III, randomised, double blind, multicentre, parallel arm, clinical study comparing the efficacy, safety, immunogenicity and pharmacokinetics of proposed biosimilar nivolumab (DRL_NU) with nivolumab reference medicinal product (OPDIVO®) administered by the intravenous route in patients previously treated for locally advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).